Clinical Trial Update: Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating pazopanib for epistaxis in hereditary hemorrhagic telangiectasia (HHT) at Phase 1/2 stages. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epistaxis
• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Cure HHT | Conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 1, Phase 2 | Status: UNKNOWN